Back to Search Start Over

A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC).

Authors :
van Praag, Veroniek M.
Rueten-Budde, Anja J.
Jeys, Lee M.
Laitinen, Minna K.
Pollock, Rob
Aston, Will
van der Hage, Jos A.
Dijkstra, P.D. Sander
Ferguson, Peter C.
Griffin, Anthony M.
Willeumier, Julie J.
Wunder, Jay S.
van de Sande, Michiel A.J.
Fiocco, Marta
Source :
European Journal of Cancer. Sep2017, Vol. 83, p313-323. 11p.
Publication Year :
2017

Abstract

Background To support shared decision-making, we developed the first prediction model for patients with primary soft-tissue sarcomas of the extremities (ESTS) which takes into account treatment modalities, including applied radiotherapy (RT) and achieved surgical margins. The PERsonalised SARcoma Care (PERSARC) model, predicts overall survival (OS) and the probability of local recurrence (LR) at 3, 5 and 10 years. Aim Development and validation, by internal validation, of the PERSARC prediction model. Methods The cohort used to develop the model consists of 766 ESTS patients who underwent surgery, between 2000 and 2014, at five specialised international sarcoma centres. To assess the effect of prognostic factors on OS and on the cumulative incidence of LR (CILR), a multivariate Cox proportional hazard regression and the Fine and Gray model were estimated. Predictive performance was investigated by using internal cross validation (CV) and calibration. The discriminative ability of the model was determined with the C-index. Results Multivariate Cox regression revealed that age and tumour size had a significant effect on OS. More importantly, patients who received RT showed better outcomes, in terms of OS and CILR, than those treated with surgery alone. Internal validation of the model showed good calibration and discrimination, with a C-index of 0.677 and 0.696 for OS and CILR, respectively. Conclusions The PERSARC model is the first to incorporate known clinical risk factors with the use of different treatments and surgical outcome measures. The developed model is internally validated to provide a reliable prediction of post-operative OS and CILR for patients with primary high-grade ESTS. Level of significance level III. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09598049
Volume :
83
Database :
Academic Search Index
Journal :
European Journal of Cancer
Publication Type :
Academic Journal
Accession number :
124932799
Full Text :
https://doi.org/10.1016/j.ejca.2017.06.032